Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 - the Apollo Trial

NCT04746339 is registered in ClinicalTrials.gov with Brazilian Clinical Research Institute as lead sponsor.

NCT NCT04746339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04746339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 - the Apollo Trial
Lead sponsor
Brazilian Clinical Research Institute
Phase
Phase 4
Overall status
Terminated
Start date
March 4, 2021
Completion date
May 30, 2022
Enrollment
411 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, thrombosis